Skip to search formSkip to main contentSkip to account menu

Inotuzumab Ozogamicin

A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

CMC-544
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
7030Background: InO, a CD22-directed antibody-drug conjugate, is approved to treat adults with R/R ALL. Historically, patients… 
Review
2017
Review
2017
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from… 
Review
2016
Review
2016
Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia
ABSTRACT Whilst most adult patients with acute lymphoblastic leukaemia will go into remission with standard induction… 
2015
2015
Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Background: Outcome of patients with R/R ALL is very poor. INO is a CD22 monoclonal antibody bound to a toxin, calecheamicin, and… 
2014
2014
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High… 
2012
2012
Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
![Graphic][1] Background InO is a humanized anti-CD22 antibody conjugated to calicheamicin. CD22 is expressed on a majority of… 
2011
2011
World Antibody Drug Conjugate Summit Europe
The World Antibody Drug Conjugate Summit Europe, organized by Biorbis/ Hanson Wade was held in Frankfurt, Germany on February 21… 
2011
2011
An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,
Abstract 3715 Background: Inotuzumab ozogamicin (INO) is a humanized anti-CD22 antibody conjugated to calicheamicin, a potent… 
2011
2011
Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)
Abstract 875 Background: Patients (pts) with R-R ALL have a poor prognosis. CD22 is highly expressed in ALL. IO is active in CD22… 
Highly Cited
2010
Highly Cited
2010
Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy
Inotuzumab ozogamicin (CMC‐544), an antibody‐targeted chemotherapeutic agent composed of an anti‐CD22 antibody conjugated to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)